U. Vanhoefer
- Oncology top 1%
- Colorectal Cancer Treatments and Studies 42
- Cancer Treatment and Pharmacology 30
- Drug Transport and Resistance Mechanisms 7
- Gastroenterology top 2%
-
- Gastric Cancer Management and Outcomes 37
- Metastasis and carcinoma case studies 10
- Hepatology top 5%
- Toxicology top 2%
-
- Cancer therapeutics and mechanisms 18
- Angiogenesis and VEGF in Cancer 8
-
- Esophageal Cancer Research and Treatment 9
U. Vanhoefer
80 papers receiving 3.0k citations
Peers
Comparison fields: 5 of 103
- Oncology 2.1k
- Gastroenterology 213
- Pulmonary and Respiratory Medicine 1.2k
- Hepatology 280
- Toxicology 78
Countries citing papers authored by U. Vanhoefer
This map shows the geographic impact of U. Vanhoefer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by U. Vanhoefer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites U. Vanhoefer more than expected).
Fields of papers citing papers by U. Vanhoefer
This network shows the impact of papers produced by U. Vanhoefer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by U. Vanhoefer. The network helps show where U. Vanhoefer may publish in the future.
Co-authorship network
The 25 scholars most cited alongside U. Vanhoefer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 0 | |
| 2 | 2023 | 1 | |
| 3 | 2009 | 2 | |
| 4 | 2007 | 2 | |
| 5 | 2007 | 40 | |
| 6 | 2006 | 3 | |
| 7 | 2005 | 25 | |
| 8 | 2005 | 31 | |
| 9 | 2004 | 63 | |
| 10 | 2003 | 46 | |
| 11 | 2003 | 19 | |
| 12 | 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors. | 2002 | 42 |
| 13 | D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. | 2001 | 131 |
| 14 | 1998 | 6 | |
| 15 | Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells. | 1997 | 5 |
| 16 | 1997 | 63 | |
| 17 | 1997 | 162 | |
| 18 | 1997 | 5 | |
| 19 | 1996 | 6 | |
| 20 | 1996 | 14 |
About U. Vanhoefer
U. Vanhoefer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Gastroenterology, having authored 84 papers that have together received 3.1k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (42 papers), Gastric Cancer Management and Outcomes (37 papers), Cancer Treatment and Pharmacology (30 papers), Cancer therapeutics and mechanisms (18 papers), Metastasis and carcinoma case studies (10 papers), Esophageal Cancer Research and Treatment (9 papers), Angiogenesis and VEGF in Cancer (8 papers) and Drug Transport and Resistance Mechanisms (7 papers). The work is most often cited by research in Oncology (2.1k citations), Gastroenterology (213 citations) and Pulmonary and Respiratory Medicine (1.2k citations). U. Vanhoefer has collaborated with scholars based in Germany, United States and Belgium. Frequent co-authors include A. Harstrick, S. Seeber, Youcef M. Rustum, H. Wilke, W. Achterrath, Shousong Cao, N. Schleucher, Eric Van Cutsem, J. Wils and Bernard Nordlinger. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Annals of Oncology, Anti-Cancer Drugs and Molecular Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.